Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Intellia Therapeutics, Inc. NTLA
$43.10
-$1.47 (-3.41%)
На 18:00, 12 мая 2023
+205.71%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
3994109415.00000000
-
week52high
76.45
-
week52low
32.44
-
Revenue
52121000
-
P/E TTM
-7
-
Beta
1.85467100
-
EPS
-6.30000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:00
Описание компании
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 05 авг 2022 г. |
| Chardan Capital | Buy | Buy | 05 авг 2022 г. |
| BMO Capital | Market Perform | 17 июн 2022 г. | |
| B of A Securities | Buy | 16 июн 2022 г. | |
| Goldman Sachs | Buy | Buy | 24 мая 2022 г. |
| Citigroup | Sell | 01 сент 2022 г. | |
| JP Morgan | Overweight | 21 сент 2022 г. | |
| SVB Leerink | Outperform | Outperform | 19 сент 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 19 сент 2022 г. |
| Morgan Stanley | Overweight | 11 окт 2022 г. | |
| EF Hutton | Buy | 01 ноя 2022 г. | |
| Chardan Capital | Buy | Buy | 15 ноя 2022 г. |
| Raymond James | Outperform | Outperform | 04 ноя 2022 г. |
| Morgan Stanley | Overweight | Overweight | 04 ноя 2022 г. |
| EF Hutton | Buy | Buy | 04 ноя 2022 г. |
| Credit Suisse | Outperform | Outperform | 04 ноя 2022 г. |
| Credit Suisse | Outperform | Outperform | 06 дек 2022 г. |
| SVB Leerink | Outperform | Outperform | 02 дек 2022 г. |
| Wells Fargo | Overweight | Overweight | 04 янв 2023 г. |
| JMP Securities | Market Perform | Market Outperform | 19 янв 2023 г. |
| Cantor Fitzgerald | Overweight | 01 февр 2023 г. | |
| Citigroup | Neutral | Sell | 24 янв 2023 г. |
| SVB Leerink | Outperform | Outperform | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Sepp-Lorenzino Laura | D | 17629 | 689 | 05 янв 2023 г. |
| Sepp-Lorenzino Laura | D | 18318 | 1641 | 05 янв 2023 г. |
| Sepp-Lorenzino Laura | D | 19959 | 2508 | 04 янв 2023 г. |
| LEONARD JOHN M | D | 766825 | 6673 | 04 янв 2023 г. |
| Hicks Derek | D | 17306 | 1812 | 04 янв 2023 г. |
| Lebwohl David | D | 25687 | 2574 | 04 янв 2023 г. |
| Goddard Glenn | D | 15404 | 2427 | 04 янв 2023 г. |
| BASTA JAMES | D | 19559 | 1138 | 04 янв 2023 г. |
| Clark Eliana | D | 14473 | 1692 | 04 янв 2023 г. |
| Clark Eliana | D | 16165 | 231 | 03 янв 2023 г. |
Новостная лента
Are You Looking for a Top Momentum Pick? Why Intellia Therapeutics, Inc. (NTLA) is a Great Choice
Zacks Investment Research
09 мая 2023 г. в 13:45
Does Intellia Therapeutics, Inc. (NTLA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Intellia Therapeutics, Inc. (NTLA) Could Surge 115.12%: Read This Before Placing a Bet
Zacks Investment Research
09 мая 2023 г. в 11:28
The consensus price target hints at an 115.1% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Intellia (NTLA) Beats on Q1 Earnings, Gives Pipeline Update
Zacks Investment Research
05 мая 2023 г. в 10:40
Intellia's (NTLA) first-quarter earnings beat estimates. The company provides updates on its gene-editing pipeline.
Intellia Therapeutics, Inc. (NTLA) Q1 2023 Earnings Call Transcript
Seeking Alpha
04 мая 2023 г. в 12:08
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Ian Karp - Senior Vice President, Investor Relations and Corporate Communications John Leonard - Chief Executive Officer David Lebwohl - Chief Medical Officer Laura Sepp-Lorenzino - Chief Scientific Officer Glenn Goddard - Chief Financial Officer Conference Call Participants Joseph Thome - TD Cowen Maury Raycroft - Jefferies Yanan Zhu - Wells Fargo Securities Dae Gon Ha - Stifel Liisa Bayko - Evercore ISI William Pickering - Bernstein Joon Lee - Truist Brian Cheng - JPMorgan Rick Bienkowski - Cantor Fitzgerald Steve Seedhouse - Raymond James Silvan Tuerkcan - JMP Securities Richard Law - Credit Suisse Operator Good morning and welcome to the Intellia Therapeutics' First Quarter 2023 Financial Results Conference Call. My name is Drew and I will be your conference operator today.
The 3 Most Promising Gene Editing Stocks to Buy in 2023
InvestorPlace
28 апр 2023 г. в 16:51
Gene editing stocks are one of the hottest sectors in medicine today. Genes are the foundation of life, and from creating new organisms to curing incurable diseases, the editing of genes can bring radical changes to life as we know it.